Is Cystatin C a promising marker of renal function, at birth, in neonates prenatally diagnosed with congenital kidney anomalies?

Paloma Parvex¹, Christophe Combescure², Maria Rodriguez³ and Eric Girardin¹

¹Pediatric Nephrology Unit, Department of Pediatric, Geneva University Hospital, Geneva, Switzerland, ²Department of Clinical Epidemiology, Geneva University Hospital, Geneva, Switzerland and ³Pediatric Research Platform, Department of Pediatric, Geneva University Hospital, Geneva, Switzerland

Abstract

Background. Despite the increased prenatal diagnosis of congenital abnormalities of the kidney and urinary tract (CAKUT), no reliable renal marker for glomerular filtration rate (GFR) has been validated yet in neonates. Cystatin C (CysC) is specific to the neonate and is proposed as a sensitive marker for this population. The aims of the study were first to define a reference interval in our center of CysC at birth in normal term babies and assess CysC as a marker of GFR in a group of term neonates prenatally diagnosed with CAKUT compared to controls.

Methods. One hundred normal term neonates (control group) and 33 neonates with kidney malformation (KM) had the CysC levels in their cord blood measured. A reference interval for CysC in controls was calculated using non-parametric methods. CysC from controls was compared first to the whole group of neonates with KM, then with KM group divided in infants (n = 20) with unilateral kidney malformation (UKM) and those (n = 13) with bilateral kidney malformation (BKM). A multivariable analysis was performed to assess the difference in CysC between the groups with adjustment on other factors. The ability of CysC to discriminate neonates with BKM from the controls was assessed by a non-parametric receiver-operated characteristics (ROC) curve.

Results. In the control group, the CysC reference interval was [1.54–2.64] mg/L with a median (M) CysC of 2.02 IQR [1.86–2.23]. In the neonates with KM, M CysC was 1.98 IQR [1.79–2.34]; 1.88 IQR [1.76–2.01] in the UKM group and 2.52 IQR [2.16–2.71] in BKM group. Using a multivariate regression analyses, CysC was significantly increased (P < 0.001) in BKM compared to controls with an increment of CysC of 24.5%, and independent from gender, weight and size. The ROC curve analyses, comparing BKM versus controls with a chosen cut-off for CysC of 2.34, showed a sensitivity of 69% and a specificity of 86%.

Conclusions. Comparing CysC with a reference interval of CysC validated in our center, we showed a significant increase of CysC in neonates presenting BKM compared to controls and those with UKM.

Keywords: congenital kidney diseases; cystatin C; neonates; reference interval; renal marker

Introduction

The assessment of renal function in neonates at birth may be particularly helpful in case of severe congenital anomalies of the kidney and urinary tract diagnosed during the prenatal period, not only to identify neonates at risk to present an abnormal decrease in glomerular filtration rate (GFR) but also to optimize nephrotoxic drugs, electrolytes and fluids prescriptions in critical situations.

For this population, no accurate renal marker is validated because the correlation with a gold standard as clearances implies serial blood samples and timed collected urine, which is challenging in neonates.

Even if plasma creatinine is widely used to evaluate renal function in children and adults, its measurement is not specific for the baby at birth since creatinine crosses the placenta and is influenced by the mother’s value for the 2–3 weeks after birth [1–3]. Cystatin C (CysC) does not cross the placenta [4, 5] and is proposed as a potential renal marker for the neonatal period. CysC is a 13 600 Da protein synthesized by a housekeeping gene in all nucleated cells, which means that its amount in the blood is constant [6, 7]. In addition, 99% of CysC is freely filtered through the glomerular membrane without significant peritubular uptake and then completely reabsorbed and degraded by the proximal tubule. Therefore, urine content of CysC is negligible and it is not a good candidate for a urine renal marker [8, 9]. Numerous studies showed that CysC is independent of gender, age and muscle mass, this being of particular importance in a paediatric population [10–12]. CysC can be easily drawn at birth on cord blood and may provide a rapidly available measure of neonatal renal function.
The aims of this study were first to validate a reference interval for CysC in our centre in a large population of normal term babies without any anomalies detected on prenatal ultrasound and compare our reference interval for Cystatin C with those published in the literature [5, 10, 11, 13–15]. Thereafter, we aimed to assess the validity of CysC levels at birth in neonates prenatally diagnosed with kidney malformations (KMs), and finally to compare the Cystatin C values in this group with the control group of normal term neonates.

Materials and methods

The protocol (CER 05-111) of this study was approved by the Ethical committee of Geneva University.

Patients

Since 2008, in the University Maternity of Geneva, term neonates without any anomalies detected on prenatal ultrasound (n = 100) and term neonates (n = 33) prenatally diagnosed with kidney anomalies were included prospectively in the study. In case of kidney dilatation, we considered for inclusion a measured anterior-posterior diameter of ≥10 mm during the third trimester of pregnancy. The repartition of the kidneys’ anomalies is described in Table 1.

We recruited the patients during the regular second (26 weeks) or third (32 weeks) prenatal visit. During this visit, we obtained written consent to measure CysC by drawing sample on cord blood in the neonates at birth. In the group of normal neonates, babies from mothers presenting complications during pregnancy as diabetes, hypertension and infection or on medication during pregnancy were not included.

Cystatin C analyses

CysC was measured by particle-enhanced nephelometric immunoassay (PENIA) on Image®-Beckman analyzer. The assay used for the reaction is from DakoCytomation. The samples were analysed within 4 h of being drawn. Samples did not require dilution and results were available within a few minutes. Only 2 mL of cord blood was required for this analysis. The coefficient of variation (CV) for CysC (inter-assay precision) was 4.95% at 1.13 mg/L and 3.30% at 4.91 mg/L (n = 130). The CV (intra-assay precision) was 2.0% at 1.71 mg/L and 2.3% at 5.37 mg/L (n = 80). Total measurement uncertainty was 0.097 mg/L at 1.14 mg/L.

Statistical analyses

The distribution of CysC in controls was described by median and inter-quartile range (IQR) (mg/L). The CysC was log-transformed to fulfill the assumption of a Gaussian distribution. It was tested using a Shapiro–Wilks’s test. The reference interval (percentiles 2.5 and 97.5%) of the logarithm of the CysC was assessed by using the non-parametric central 95% confidence interval method and by a robust method following the Clinical and Laboratory Standards Institute guidelines (CLSI C28-A3) and back-transformed in the natural scale of the CysC. The confidence interval of the estimates of CysC reference interval was obtained by bootstrap (re-sampling 100 000 times). To check the robustness of the estimate reference interval for the characteristics of the subjects, it was assessed in subgroups according to gender, weight and size by using the robust method.

Results

CysC reference interval

We obtained CysC values in 100 term babies. Fifty-six were girls (56%). The median for weight was 3.50 kg IQR [3.23–3.79], for size 51 cm IQR [50–53] and for GA 40 weeks IQR [40–41].

Median cord blood CysC in normal term babies was 2.02 mg/L IQR [1.86–2.23].

The assumption of a Gaussian distribution was rejected for CysC (P = 0.02) but was adequate for the logarithm of CysC (P = 0.25). By using the non-parametric central 95% confidence interval method, the reference interval was [1.61–2.70]. The 95% confidence interval for the assessed low normal value was [1.47–1.67] and [2.52–2.71] for the high value.

By using the robust method, the reference interval was [1.54–2.64]. The 95% confidence interval for the assessed low normal value was [1.47–1.61] and [2.51–2.78] for the high value. The results from both methods were similar.

When the reference intervals were assessed in subgroups according to gender, weight and size, the lower normal value ranged from 1.49 to 1.63 and the upper normal value from 2.49 to 2.63.

Table 1. Details of the different patient’s congenital kidneys anomalies

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>UKM (pts = 20)</th>
<th>BKM (pts = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD† ≥10 mm</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Post-urethral valves</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>MCKD</td>
<td>2</td>
<td>2/PD and 2/DK</td>
</tr>
<tr>
<td>Ectopic dysplastic (pelvic) (DK)</td>
<td>2</td>
<td>1/PD</td>
</tr>
<tr>
<td>RA</td>
<td>2</td>
<td>1/DK</td>
</tr>
<tr>
<td>Hypoplastic kidney</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

†DK, dysplastic kidney; PD, pelvic dilatation; RA, renal agenesis; pts, patients.

CysC in neonates with KM

Among the 33 babies (22 boys; 11 girls) with KM, 20 had UKM and 13 had BKM. Neonates with UKM had the following diagnosis: 12 renal pelvic dilatation ≥10 mm, 2 multicystic kidney disease (MCKD), 2 pelvic dysplastic kidneys, 2 renal agenesis and 2 hypoplastic kidneys. Among the neonates with BKM, five patients (pts) presented with bilateral renal pelvic dilatation ≥10 mm, two pts with post-urethral valves, two pelvic dilatation ≥10 mm/MCKD, one ectopic dysplastic kidney/MCKD, one
pelvic dilatation ≥10 mm/ectopic dysplastic kidney, one MCKD/dysplastic kidney (TCF2 mutation) and one patient renal agenesis/ectopic dysplastic kidney (Table 1).

The control group and the KM group were different in weight (P < 0.001) and size (P < 0.003) (Table 2), justifying a multivariate analysis with adjustment on these factors (Table 3).

CysC in the KM group was not statistically different from the control group (P = 0.83). The distribution of Cystatin C values of each group is illustrated in the box-plot (Figure 1). The median CysC in each group was: 1.98 IQR [1.79–2.34] in the KM group, 1.88 IQR [1.76–2.01] in the UKM group and 2.52 IQR [2.16–2.71] in the BKM group.

The univariate analysis (not shown) yielded similar results than the multivariate analyses reported in Table 3. In the multivariate analyses, we confirmed that CysC was not influenced by gender and weight. Compared to controls, CysC in the BKM group was significantly increased (P < 0.001) with an augmentation of 24.5%. The UKM group had lower values of CysC (P = 0.007) but the decrease was weak (6.9%).

The ROC curves, analysing BKM versus control, showed a cut-off for CysC of 2.16, a sensitivity of 76.9% [46.2; 95.0] and a specificity of 73.0% [63.2; 81.4]; with a value of 2.34, a sensitivity of 69.2% [38.6; 90.9] and a specificity of 86.0% [77.6; 92.1] and with 2.48, a sensitivity 61.5% [31.6; 86.1] and a specificity of 92.0% [84.8; 96.5] (Figure 2).

Discussion

Because congenital kidney anomalies represent 30% of total anomalies diagnosed prenatally [16], the revelation during pregnancy by ultrasound of a kidney anomaly has become a frequent reason for nephrology prenatal counseling. This increase is due principally to technical advances and a better follow-up of pregnancies. Consequently, the need to progress in the determination of a useful renal marker for the neonatal period has become more and more necessary, not only to improve neonatal care but also to inform the parents on long-term prognosis. Assessment of renal function before birth is not accurate and even if the amount of amniotic fluid is widely used, it is a weak indicator of neonatal renal function and nowadays, none of the prenatal renal markers proposed have been validated [17–20]. Bokenkamp et al. proposed that reference values for CysC in fetal serum could be predictors for renal function, and obtained by 129 cordocenteses, values in 84 fetuses. Among these, he defined in a group of 54 fetuses without kidney disease a mean CysC of 1.66 ± 0.202 mg/L and a reference interval using parametric method of [1.26–2.06] mg/L. However, the dosage of serum fetal CysC cannot be performed routinely because of the risk of fetal loss associated with fetal blood puncture [4].

The absence of an accurate prenatal marker highlights the necessity to measure renal function at birth particularly in neonates presenting bilateral kidney anomalies. Creatinine widely used to assess renal function is not useful at birth to identify neonates susceptible to present renal failure. Guignard et al. [2, 3] demonstrated that creatinine rises during the first 48 h of life and this increase was even greater in premature infants. Moreover, creatinine does not reflect the neonates’ value during the first 2 weeks of life [2, 3, 21, 22]. These authors report that the increased creatinine immediately after birth is not only secondary to mother transfer in the neonate but also to a temporary increased creatinine reabsorption by the kidney attributed to tubular immaturity of the newborn [2].

It is now recognized that CysC is specific for the fetus, implying its use as a potentially valuable renal marker for neonates [4, 5, 13]. Akbari et al. [23] showed the progressive rise of Cystatin C in relation with GA in pregnant women with higher values during the third trimester. Despite this mother’s CysC increases during pregnancy, many authors confirmed the lack of correlation between maternal and fetal CysC [4, 18, 24]. The measure of CysC in urine and amniotic fluid has been tested in fetuses with renal obstruction by different authors without the possibility to establish reference values for CysC in this condition [17, 24, 25].

CysC reference interval

In the newborn, the validation of a potential renal marker using a gold standard for GFR is complicated by the need of repeated blood samples and the difficulty to obtain accurate urine collections.

Because of the difficulty to compare CysC at this age with a recognized gold standard, we validated in our centre a reference interval using the Clinical and Laboratory Standards Institute (CLSI C28-A3) guidelines and calculate reference interval using the robust method as described in CLSI guidelines. Two methods are available and recognized for the measurement of CysC; PENIA and particle-enhanced turbidimetric immunoassay (PETIA) [8]. The method used in our centre is PENIA which is reported to be more sensitive than PETIA [8]. We report here CysC values in 100 normal term babies and established a reference interval for CysC of [1.54–2.64 mg/L] and the median value for CysC was 2.02 mg/L.

The estimation of the confidence interval for normal values was similar using both non-parametric and robust methods and confirmed the robustness of the results obtained with these statistical analyses. In our sample, the robustness of the CysC reference interval was checked in the subgroup and showed no clinically meaningful variability of CysC with gender, weight and size. The literature reports reference interval for normal term newborns [5, 10, 13–15, 26, 27] and premature [10, 14, 21, 26, 28] at birth. We compared our results with published data available for term babies at birth. Bahar et al. [13], reported lower values than ours, with a mean CysC of 1.36 ± 0.35 mg/L measured by PENIA method, taken from cord blood in 112 newborns. Treiber et al. measured using the same methods (PENIA), CysC cord blood value in 75 newborns and found a cord blood value with a mean CysC value of 1.97 ± 0.36 quite similar to our value of 2.02. Harmoinen et al. analysed 50 full-term infants and proposed a mean CysC value (PETIA) of 1.70 mg/L ± 2.6 SD and a reference interval of CysC in term babies of [1.36–2.23] mg/L. Bokenkamp et al. report a mean CysC
similar to our results. Barician et al. measured CysC on Day 1 and Day 3 in 128 neonates, aged from ≥24 to ≥36 weeks. In the group of term babies (≥36 weeks) corresponding to our group, 24 neonates had CysC measured on Day 1 and 21 on Day 3; median CysC was 1.84 mg/dL and the reference interval of [1.32–2.63].

Numerous studies evaluated the interest of CysC to predict GFR in adult and in older children and found a good correlation with a recognized gold standard [6, 10, 15, 30, 31]. Only a few have studied the correlation of CysC with a gold standard in neonates. This was done by Montini et al. who measured GFR in 20 premature neonates (28–34 weeks of gestation) using single-shot inulin clearance where inulin was injected through a central catheter previously inserted for clinical reason. Then the authors compared CysC and creatinine GFR obtained with inulin clearance; infants with a GFR <0.5 mL/min/1.73 m$^2$ had CysC >2 mg/L and inversely premature with normal clearance >0.5 mL/min/1.73 m$^2$ had CysC <2 mg/L [13]. Different CysC-based formulas to derive GFR from CysC were described but none have been validated yet for neonates [4, 31].

Using a regression analysis, the authors showed no significant correlation between GA and CysC on Day 3, whereas there was a weak, but significant, positive correlation on Day 1 ($r = 0.275$, $P = 0.0037$); however, they analysed a population with different GA. In our population, we did not observe a relationship with GA, most likely because our infants had a GA >36 weeks [29].

To assess the validity of CysC at birth in neonates with congenital renal anomalies, we compared the group presenting malformation of the kidneys with the group of

(PETIA) of 2.02 mg/L and a range of 1.64–2.59 mg/L similar to our results. Barician et al. measured CysC on Day 1 and Day 3 in 128 neonates, aged from 24 to ≥36 weeks. In the group of term babies (≥36 weeks) corresponding to our group, 24 neonates had CysC measured on Day 1 and 21 on Day 3; median CysC was 1.84 mg/dL and the reference interval of [1.32–2.63].

CysC in neonates with prenatal diagnosis of KM

To assess the validity of CysC at birth in neonates with congenital renal anomalies, we compared the group presenting malformation of the kidneys with the group of
normal term babies. The multivariate analyses confirmed that CysC was not influenced by gender, weight and size and both groups were comparable.

We observed that the median CysC for the entire group of KM was 1.98 mg/L and not statistically different from the control group 2.02 mg/L. When analysing separately neonates presenting UKM or BKM, interestingly, we found in neonates with BKM, a significantly increased mean CysC compared to the control group (P < 0.001) with a CysC increment of 24.5%. In our population, a high level of CysC in neonates with BKM may reflect the low renal endowment in these neonates. In normal term babies, the nephron mass is complete at birth. However, impaired kidney development occurs in neonates with congenital kidney anomalies leading likely to a lower number of nephrons at birth and an increased risk to present lower renal function at birth [32–35]. Compensatory mechanisms such as hyperfiltration of the residual nephrons will take place later in these infants leading to a pre-disposition to future hypertension and renal insufficiency [35, 36].

Surprisingly, mean CysC in neonates with UKM was significantly lower from the control group. One of the explanations could be the lower weight of the neonates in this group, but the multivariate analyses showed no impact of weight on CysC values. Another reason may be the small sample size of this group (n = 20). We hypothesize that this decrease in CysC could be secondary to hyperfiltration of the nephrons of the opposite normal kidney. To analyse this hypothesis, we calculate the length of the kidneys to seek for a possible hypertrophic growth of the normal opposite kidney with sizes reported as z-score for length (results not shown). The difference was not significant, probably biased by the fact that the principal kidney anomaly in this group was pelvic dilated kidney with an increased size.

Finally, we were interested to propose a cut-off CysC value that may be used as an indicator of an increased risk to present reduced renal function at birth; we used ROC curve analyses and compared neonates with BKM versus controls. With a chosen cut-off of 2.34 mg/L, the sensitivity to present a bilateral anomaly was 69% with a CysC increment of 24.5%. In our population, a high level of CysC in neonates with BKM may reflect the low renal endowment in these neonates. In normal term babies, the nephron mass is complete at birth. However, impaired kidney development occurs in neonates with congenital kidney anomalies leading likely to a lower number of nephrons at birth and an increased risk to present lower renal function at birth [32–35]. Compensatory mechanisms such as hyperfiltration of the residual nephrons will take place later in these infants leading to a pre-disposition to future hypertension and renal insufficiency [35, 36].

Surprisingly, mean CysC in neonates with UKM was significantly lower from the control group. One of the explanations could be the lower weight of the neonates in this group, but the multivariate analyses showed no impact of weight on CysC values. Another reason may be the small sample size of this group (n = 20). We hypothesize that this decrease in CysC could be secondary to hyperfiltration of the nephrons of the opposite normal kidney. To analyse this hypothesis, we calculate the length of the kidneys to seek for a possible hypertrophic growth of the normal opposite kidney with sizes reported as z-score for length (results not shown). The difference was not significant, probably biased by the fact that the principal kidney anomaly in this group was pelvic dilated kidney with an increased size.

Finally, we were interested to propose a cut-off CysC value that may be used as an indicator of an increased risk to present reduced renal function at birth; we used ROC curve analyses and compared neonates with BKM versus controls. With a chosen cut-off of 2.34 mg/L, the sensitivity to present a bilateral anomaly was 69% with a high specificity of 86%. This value may discriminate in case of kidney anomalies neonates with lower renal function at birth. However, the sample size was not sufficient to validate this cut-off.

In conclusion, CysC values in neonates presenting a unilateral kidney anomaly were similar to controls whereas CysC was significantly increased in infants presenting a bilateral kidney anomaly. Although we are aware that the validity of CysC in neonates will not be complete without a correlation with a gold standard, CysC may be a useful marker, readily available at birth on cord blood in neonates prenatally diagnosed with congenital renal diseases, to identify those susceptible to present decreased renal function.

Conflict of interest statement. None declared.

(See related article by Filler et al. Cystatin C for the assessment of GFR in neonates with congenital renal anomalies. Nephrol Dial Transplant 2012; 27: 3382–3384.)
Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease

Dana V. Rizk1, Orlando Gutierrez1, Emily B. Levitan2, William M. McClellan2,3, Monika Safford4, Elsayed Z. Soliman5, David G. Warnock1 and Paul Muntner1,2

1Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA, 2Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA, 3Division of Nephrology, Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA, 4Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA and 5Department of Epidemiology and Prevention, Epidemiological Cardiology Research Center (EPICARE), Wake Forest University School of Medicine, Winston-Salem, NC, USA

Correspondence and offprint requests to: Dana V. Rizk; E-mail: drizk@uab.edu

Abstract

Background. Unrecognized myocardial infarctions (UMIs) are common in the general population but have not been well studied in patients with chronic kidney disease (CKD). The purpose of this study was to determine the prevalence and prognosis for mortality of UMI among adults with CKD.

Methods. The current study included 18,864 participants in the population-based REasons for Geographic And Racial Differences in Stroke (REGARDS) study who completed a baseline examination including a 12-lead electrocardiogram (ECG). UMI was defined as the presence of myocardial infarction (MI) by Minnesota ECG classification in the absence of self-reported or recognized MI (RMI). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation and albuminuria using albumin-to-creatinine ratio from a spot urine sample. All-cause mortality was assessed over a median 4 years of follow-up.

Results. The prevalence of UMI was 4, 6, 6 and 13% among participants with eGFR levels of ≥60, 45–59.9, 30–44.9 and <30 mL/min/1.73m², respectively, and 4, 5, 7 and 10% among participants with albuminuria levels of <10, 10–29.9, 30–299.9 and ≥300 mg/g, respectively. Compared to those with no MI, the multivariable adjusted hazard ratio for all-cause mortality associated with UMI and RMI was 1.65 [95% confidence interval (CI): 1.09–2.49] and 1.65 (95% CI: 1.20–2.26), respectively, among individuals with an eGFR <60 mL/min/1.73m² and 1.49 (95% CI: 1.03–2.16) and 1.88 (95% CI: 1.40–2.52) among individuals with albuminuria ≥30 mg/g.

Conclusion. UMIs are common among individuals with an eGFR <60 mL/min/1.73m² and albuminuria and associated with an increased mortality risk.

Keywords: chronic kidney disease; coronary artery disease; mortality